Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes

Abstract

Aims/hypothesis We sought to subtype South East Asian patients with type 2 diabetes by de novo cluster analysis on clinical variables, and to determine whether the novel subgroups carry distinct genetic and lipidomic features as well as differential cardio-renal risks. Methods Analysis by k-means algorithm was performed in 687 participants with recent-onset diabetes in Singapore. Genetic risk for beta cell dysfunction was assessed by polygenic risk score. We used a discovery–validation approach for the lipidomics study. Risks for cardio-renal complications were studied by survival analysis. Results Cluster analysis identified three novel diabetic subgroups, i.e. mild obesity-related diabetes (MOD, 45%), mild age-related diabetes with insulin insufficiency (MARD-II, 36%) and severe insulin-resistant diabetes with relative insulin insufficiency (SIRD-RII, 19%). Compared with the MOD subgroup, MARD-II had a higher polygenic risk score for beta cell dysfunction. The SIRD-RII subgroup had higher levels of sphingolipids (ceramides and sphingomyelins) and glycerophospholipids (phosphatidylethanolamine and phosphatidylcholine), whereas the MARD-II subgroup had lower levels of sphingolipids and glycerophospholipids but higher levels of lysophosphatidylcholines. Over a median of 7.3 years follow-up, the SIRD-RII subgroup had the highest risks for incident heart failure and progressive kidney disease, while the MARD-II subgroup had moderately elevated risk for kidney disease progression. Conclusions/interpretation Cluster analysis on clinical variables identified novel subgroups with distinct genetic, lipidomic signatures and varying cardio-renal risks in South East Asian participants with type 2 diabetes. Our study suggests that this easily actionable approach may be adapted in other ethnic populations to stratify the heterogeneous type 2 diabetes population for precision medicine. Graphical abstract

Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022

“…Due to the elevated risk of mortality with these diseases, there is a need for strategies in its identification, prevention, and treatment within healthcare. In 2022, as evidenced in Figure 5, the bulk of research articles focussed on related diseases: CVD, 232–255 diabetes, 166,233,249,250,256–278 liver disease, 51,279–293 MetS 277,294,295 and obesity 277,295–305 …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 using Scopus search terms “lipidomics” AND “clinic*” on 15 th December 2022 …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 according to separation techniques, detectors, and RPLC columns used …”

Metabotyping: a tool for identifying subgroups for tailored nutrition advice

“…Although the ANDIS clusters have been replicated in several populations, a study in a Singaporean cohort highlights the impact of certain ethnicities on disease profile and progression and the importance of testing the metabotyping model in the target population before considering its application (44) . Using the same ANDIS method and markers (except for glutamate decarboxylase antibody that determined autoimmune diabetes), a total of three clusters were reported.…”

The relationship between glycated haemoglobin and blood glucose‐lowering treatment trajectories in type 2 diabetes: The Fremantle Diabetes Study Phase II

“…The design of the present study, and many of those in which only glycaemic trajectory groups have been identified, 1 was different from those in which distinct clusters of people with subtypes of adult-onset diabetes have been proposed. 29,30 In these latter studies, apart from not using HbA1c trajectories in the categorization process, only newly 29 or recently diagnosed 30 participants were included, the subgroups were based on multiple clinical/laboratory variables and endpoints that included biochemical and genetic tests that may not be available in routine clinical care, and follow-up was limited to ≤8 years.…”